Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761810 · ClinicalTrials.gov registry record · Phase 3
A Study of S6G5T3 in the Treatment of Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 434
- Enrollment target
- 1
- Study location
NCT03761810: Completed Phase 3 study of Acne Vulgaris, sponsored by Sol-Gel Technologies.
NCT03761810 is a Phase 3 study of Acne Vulgaris that has completed, run by Sol-Gel Technologies. The registered enrollment target is 434 participants, above the 269-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03761810, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 434 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
Primary Outcome
Percentage of participants in each treatment group achieving an acne severity IGA score of "clear (score=0)" or "almost clear (score=1)" and achieving an acne severity IGA score of at least 2 grades less than Baseline.
Conditions Studied
Interventions
- DRUG S6G5T-3
- DRUG S6G5T-8
Study Locations (1)
Florida
- Sol-Gel site 501 - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2019-10-23 |
| Phase | Phase 3 |
What the finished NCT03761810 record still lists
NCT03761810 is an interventional study that assigns participants to a tested intervention. The registered 434 participants enrollment target is mid-sized for trials with a published cap, above the 269-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (61% higher).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which S6G5T-3 is the first listed.
NCT03761810 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03761810 about?
NCT03761810 is a clinical study titled "A Study of S6G5T3 in the Treatment of Acne Vulgaris". To assess the efficacy of S6G5T-3 compared to its vehicle when applied once daily for 12 weeks in participants with acne vulgaris.
What is the current status of trial NCT03761810?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 434 participants. The study started on 2018-12-14. Estimated completion is 2019-10-23.
What conditions does trial NCT03761810 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03761810?
The interventions under investigation include: S6G5T-3 (DRUG), S6G5T-8 (DRUG).
Who is sponsoring clinical trial NCT03761810?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03761810 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03761810's enrollment target sits among peer trials
434 18th of 67 higher than 50 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
-
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04743245 · 434 participants · NA
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
- NCT06471920 · 434 participants · NA
Improving Health for Patients With Chronic LBP in Rural Communities Through Telerehabilitation
- NCT07094113 · 434 participants · Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI